NSE · SENORES · Pharmaceuticals
Senores Pharmaceuticals Limited
Revenue & net profit by period
Bars = revenue (₹ Cr) · line = net profit (₹ Cr). Straight from disclosed results.
Latest period: revenue ₹27 Cr with net profit ₹1 Cr — a 3.82% net margin, versus 23.04% the period before.
Shareholding
As of 2026-06-30
- Promoter45.82%
- Public37.79%
- FII6.62%
- DII9.77%
36,498 shareholders on record
Promoter holding trend
Each disclosed period, oldest to newest
52-week position
Where the current price sits in its yearly band
The band spans 2.41× from low to high.
Risk flags
Derived from disclosed data
No flags raised by the data.
Peer comparison
Pharmaceuticals - Indian - Formulations · ranked #10 of 50 by market cap · medians across 43 industry peers
| Company | Mkt cap | P/E | P/B | ROE | Margin |
|---|---|---|---|---|---|
| Torrent Pharmaceuticals Limited | ₹1,83,052 Cr | 82.04 | 21.82 | 25.49% | 13.95% |
| Gland Pharma Limited | ₹46,642 Cr | 40.71 | 4.51 | 9.92% | 16.78% |
| Ajanta Pharma Limited | ₹43,847 Cr | 38.64 | 9.66 | 23.33% | 19.65% |
| Rubicon Research Limited | ₹29,245 Cr | 101.48 | 22.65 | 19.14% | 14.89% |
| Caplin Point Laboratories Ltd. | ₹19,634 Cr | 29.51 | 5.83 | 17.88% | 29.09% |
| Shilpa Medicare Ltd. | ₹18,151 Cr | 63.83 | 7 | 9.39% | 17.67% |
| Eris Lifesciences Limited | ₹18,060 Cr | 27.49 | 4.64 | 15.87% | 20.04% |
| Marksans Pharma Limited | ₹14,340 Cr | 27.76 | 4.74 | 13.82% | 16.29% |
| Bliss GVS Pharma Ltd. | ₹7,236 Cr | 52.55 | 6.06 | 10.82% | 13.55% |
| Senores Pharmaceuticals Limited(this company) | ₹6,341 Cr | 50.18 | 6.76 | 12.36% | 18.59% |
AI analysis
AI-generated · google/gemini-2.5-flashSenores Pharmaceuticals Limited is listed on the Indian markets with a market capitalization of Rs 6378 Cr. The company reported revenue of Rs 417.51 Cr, which increased by 85.7%. The profit margin for the latest annual period was 18.32%.
Positives
- +Revenue grew by 85.7% to Rs 417.51 Cr in the latest annual reporting period.
- +The profit margin of 18.32% indicates efficient operations.
- +The Return on Capital Employed (ROCE) is 14.4278% and Return on Equity (ROE) is 12.36%.
Negatives
- −Promoter pledge increased from 0% in March 2025 to 2.81% in June 2026.
- −Promoter holding decreased from 66.6631% in July 2024 to 45.817% in June 2026.
- −The company's P/E ratio is 55.29, which is relatively high.
Financial Performance
For the period ending March 2025, Senores Pharmaceuticals Limited reported revenue of Rs 417.51 Cr, marking an increase of 85.7%. The net profit for the same period was Rs 58.56 Cr. The company's EPS stood at Rs 25.05. In the most recent quarter (March 2026), revenue was Rs 175.19 Cr with a net profit of Rs 31.61 Cr.
Profitability & Returns
Senores Pharmaceuticals Limited achieved an annual profit margin of 18.32%. The Return on Equity (ROE) was 12.36%, and the Return on Capital Employed (ROCE) was 14.4278%. The Earnings Per Share (EPS) for the latest annual period was Rs 25.05, while the PE ratio was 55.29.
Balance Sheet
The company's book value is Rs 202.72. The debt-to-equity ratio stands at 0.58. This indicates the proportion of debt financing relative to equity financing on the company’s balance sheet.
Ownership & Pledges
As of June 30, 2026, promoters held 45.817% of the company's shares. Foreign Institutional Investors (FIIs) held 6.6183%, and Domestic Institutional Investors (DIIs) held 9.7703%. The public shareholder holding was 37.7944%. A portion of the promoter holding, specifically 2.81%, was pledged. One promoter, Mukur Yogeshkumar Barot, pledged 193,000 shares, representing 42.25% of their holding as of June 30, 2026.
Data as of — price: 2026-09-17 · financials: Jun 26 · shareholding: Jun 26. Figures are restated only when the company files again, so a period shown here is the most recent one on record — not necessarily the current quarter.
How this is produced: every figure above is computed from exchange filings and financial data mirrored by IPO Plus — no figure is generated or estimated. This is a factual summary for information and education only. It is not investment advice, not a recommendation to buy, sell or hold any security, and contains no price targets. Verify against the company's filings and the exchanges before any decision.
Back to Senores Pharmaceuticals Limitedshare price & fundamentals